Back to search results

Lifestyle Intervention for Myeloproliferative Disorders

This study, called "I Can Move With Purpose Now!", is looking at a 12-week program called the Cardiac Lifestyle Program (CLP) for people with myeloproliferative disorders (MPN), which are types of blood cancers. The CLP helps you learn to be more active and eat healthier. Researchers want to see if people with MPN can successfully complete at least 9 weeks of this program. You might be able to join if you are 18 or older and have certain types of MPN, like essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF) with a low or intermediate-1 risk. This is a pilot study, meaning it's the first time this program is being tested in MPN patients. The study is currently unclear about its recruitment status and plans to enroll about 30 people.

Study design
This is a single-arm pilot study, meaning all participants will receive the Cardiac Lifestyle Program. About 30 people are expected to take part.
What's involved
You would participate in a 12-week program that includes virtual and in-person classes, an in-clinic visit, questionnaires, and blood work.
Compensation
Not stated in the trial record.
Follow-up
Your participation is expected to last 12 weeks, with follow-up on program completion measured up to 3 months after the last patient enrolls.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05842603

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~30 participants
Updated 2025-09-25 on ClinicalTrials.gov
What's tested:Cardiac Lifestyle Program

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants that Complete at Least 9 Weeks of the 12 week Program
Measured over Enrollment to end of the 3 month follow-up of last patient enrolled

Conditions

Myeloproliferative Disorders
Leukemia

Explore related trials

Myeloproliferative Neoplasm

Where it's being run

3 sites across 1 states
Massachusetts3

Study leadership

  • Gabriela Hobbs, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Gabriela Hobbs, MD
[email protected]
617-724-1124
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 years of age
Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study.

Exclusion

ECOG performance status \>2.
Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.

What this trial measures

  • Number of Participants that Complete at Least 9 Weeks of the 12 week ProgramEnrollment to end of the 3 month follow-up of last patient enrolled

    Feasibility of this pilot trial will be measured by the number of participants that complete at least 9 weeks of the exercise program. This trial will be considered feasible if at least 70% (≥21) of participants complete the program. Completion rates will be measured with a 95% confidence interval for the adherence proportion calculated by exact binomial method.